Analysts & Consensus

Several banks and brokerages regularly cover Merck KGaA, Darmstadt, Germany, by publishing analyses, short reviews and updates.

VARA Consensus

Merck KGaA, Darmstadt, Germany, is covered by several renown sell-side analysts who make financial projections on the company. We authorize VARA Research to compile an accurate and up to date consensus of these various projections that are published once per quarter. Our company does not endorse these estimates and the figures are gathered independently by VARA Research.

The most recent analyst consensus provided by VARA Research is listed below.

VARA Consensus expectations for Q1 2024 (as of May 2024)

in € Million
High Mean Low
Net sales 5,247.0 5,101.0 4,979.9
EBITDA (pre one-time items) 1)
1,415.0 1,356.4 1,252.6
EPS (pre one-time items) 1)
€ 2.07
€ 1.93
€ 1.76

VARA Consensus expectations for Full Year 2024 (as of May 2024)

in € Million
High Mean Low
Net sales 21,452.6 21,204.4 20,770.9
EBITDA (pre one-time items) 1)
6,032.1 5,931.4 5,819.0
EPS (pre one-time items) 1)
€ 9.09
€ 8.58
€ 8.12
       
  1) For reconciliation details on EBITDA (pre one-time items) and EPS (pre one-time items) see the quarterly financial statement of Merck KGaA, Darmstadt, Germany.

Consensus on recently published Share Price Targets and Recommendations (as of May 2024)

  Buy Hold  Sell Average
Target share price in €
183.76 165.50 n/a 181.84

Analyst Coverage

Broker Analyst Broker Analyst
Barclays Capital Emily Field Jefferies Brian Balchin
Bernstein SG Florent Cespedes JP Morgan Richard Vosser
BofA Sachin Jain Kepler Cheuvreux David Evans
Citigroup  Peter Verdult LBBW Timo Kuerschner
Deutsche Bank Falko Friedrichs Morgan Stanley Thibault Boutherin
DZ Bank Peter Spengler Morningstar Julie Utterback
Equita SIM Davide Marchesin ODDO BHF Bank Oliver Metzger
Exane BNP Paribas Gary Steventon Redburn Atlantic Simon Baker
Fairesearch (Alphavalue) Martin Schnee Stifel Dylan van Haaften
HSBC Rajesh Kumar UBS Matthew Weston

Disclaimer

The Vara Research documents have been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.The details otherwise specified above are no more than the results of analyses, reports, studies, recommendations and assessments provided by third parties, particularly by analysts. The details are not based on research conducted by Merck KGaA, Darmstadt, Germany itself. Merck KGaA, Darmstadt, Germany has merely collected this data and information and would like to bring it to your attention, though without making its own recommendations or assessments. Note, in particular, that the above-mentioned details are not recommendations or offers to purchase or sell EMD shares or other financial instruments. Merck KGaA, Darmstadt, Germany does not necessarily share the conclusions, recommendations or views expressed by the analysts providing the details and does not confirm the correctness or the suitability of the above-mentioned details or of the underlying information. Merck KGaA, Darmstadt, Germany accepts no liability for the selection, quality, completeness, up-to-dateness or correctness of the assessments and recommendations specified therein. Merck KGaA, Darmstadt, Germany accepts no liability for damage arising from the information provided on this internet site.